A new report from The Royal College of Radiologists is warning that a severe shortage of radiologists in the UK is risking timely diagnosis of cancer.
News
NICE backing for Bayer’s Stivarga in GIST
Bayer’s Stivarga is being backed by the National Institute for Health and Care Excellence as a cost-effective option for the treatment of adults with gastrointestinal stromal tumours (GIST).
Health and care leaders fear winter will cripple NHS
More than 90 percent of health and care leaders across England say they are “concerned” about their organisation’s ability to cope with demand this winter, with the majority (63 percent) citing “extreme” concern.
MSD pulls plug on cholesterol drug anacetrapib
MSD has decided to pull the plug on its late-stage cholesterol drug anacetrapib after a review of clinical data.
Myeloma UK trial to test novel myeloma treatment approach
Myeloma UK has launched a nationwide trial aiming to assess the effectiveness of a novel treatment combination that includes Darzalex for patients with genetically-defined high-risk myeloma.
Pfizer considers sale of consumer health division
Pfizer says it is considering the future of its massive consumer health division, with options including a full or partial separation of the business through a spin-off, sale or other transaction, or keeping hold of the unit.
Merck buys into KalVista and its DME candidate
Shares in KalVista Pharmaceuticals have surged on news of a deal with Merck & Co potentially worth more than $750 million.
Lilly’s Verzenio misses key survival goal in lung cancer
Eli Lilly’s breast cancer drug Verzenio has failed to improve overall survival in a late-stage study assessing the drug’s potential in patients with KRAS-mutated, advanced non-small lung cancer (NSCLC).
Future quality of NHS and social care is ‘precarious’, says CQC
The future of the health and social care system is in peril as it struggles to cope with the increasingly complex needs of a 21st century population, the Care Quality Commission has warned.
Akcea’s rare lipid disorder drug wins PIM status
Akcea Therapeutics’s volanesorsen has been granted a Promising Innovative Medicine designation by the Medicines and Healthcare products Regulatory Agency for the treatment of familial chylomicronaemia syndrome, a rare genetic lipid disorder.
GamaMabs licences AZ technology for new cancer therapy
French biotech GamaMabs Pharma has licensed technology owned by AstraZeneca’s MedImmune to research and produce a novel antibody-drug conjugate (ADC) to treat cancer.
AZ’ lung cancer drug Tagrisso bags breakthrough status
AstraZeneca’s Tagrisso has been awarded breakthrough status in the US as a first-line treatment for a specific type of non-small cell lung cancer (NSCLC), potentially speeding up its development and regulatory pathway.
Darzalex, Epclusa will be funded on NHS Scotland
Patients in Scotland with multiple myeloma and those with some types of hepatitis C have won NHS access to new treatment options after the Scottish Medicines Consortium backed routine use of Janssen’s Darzalex and Gilead’s Epclusa.
AbbVie’s Venclyxto now available through CDF
AbbVie’s Venclyxto is now available on the National Health Service in England via the Cancer Drugs Fund for patients with difficult to treat forms of chronic lymphocytic leukaemia (CLL), on the recommendation of the National Institute for Health and Care Excellence.
Janssen’s HIV combo pill hits safety, efficacy targets
Janssen Pharmaceutica’s experimental combination therapy for HIV containing four medicines in a single pill has hit safety and efficacy targets in a late stage trial, results of which have been published in The Lancet HIV.
